Skip to main content Skip to navigation

[University home]

School of Medicine

Dr Andrew Renehan PhD FRCS FDS

Photograph of Andrew Renehan

Clinical Senior Lecturer/Honorary Consultant

Department of Surgery
Christie Hospital NHS Trust
Wilmslow Road
Manchester
M20 4BX

 

Role

Since January 2007, I have been a HEFCE-awarded “new-blood” senior lecturer in the School of Cancer and Imaging Sciences at the University of Manchester (UoM), and Honorary Consultant Colorectal Surgeon at the Christie NHS Foundation Trust, Manchester. My work is divided 50: 50 between research and clinical service in a bi-weekly timetable.

At a clinical level, I am one of four colorectal surgeons working within a wider pelvic surgery team (urology, gynaecology and plastic surgery) in one of the largest cancer dedicated hospitals in Europe managing advanced and complex colorectal and pelvic malignancies (Director: Miss Sarah T O’Dwyer). I am core member of the Peritoneal Tumour Service – one of two NCG national treatment centres for the peritoneal surface malignancies. I am research lead on clinical studies through this group.

My academic activities are within the research School of Cancer and Imaging Sciences (Head: Professor Tony Whetton), UoM, and the Manchester Cancer Research Centre (Director: Professor Nic Jones). I am lead for the colorectal cancer focus group within a large Cancer Research UK core-funded translational laboratory (Clinical and Experimental Pharmacology: Professor Caroline Dive) located within the Paterson Institute for Cancer Research (PICR) at the Christie campus. My laboratory group is the colorectal cancer and obesity group. I am co-chair of the Cancer Prevention Research Network and the Systematic Review Research and Educational Network (SyREN) within the Institute of Health Sciences. (see Research for links). 

 

Memberships of Committees and Professional Bodies

  • General Medical Council
  • Royal College of Surgeons of England
  • Association of Surgeons of Great Britain and Ireland
  • Association of Coloproctology of Great Britain and Ireland
  • British Journal of Surgery Society
  • Insulin-like Growth Factor (IGF) Society
  • Manchester Medical Society
  • International Society for Obesity Research
  • International Association for Cancer Prevention Research

Research

Obesity, IGFs and cancer: As a prelude to the study of potential mechanisms linking obesity with increased cancer risk, we have initially focused on the establishment of robust clinical epidemiological observations. Through a key collaboration with Prof Matthias Egger’s group (University of Bern, Switzerland), we undertook a systematic review and meta-analysis (224 cohort studies across 20 cancer types), using standardised approaches (Renehan et al. Lancet 2008), and quantified and ranked associations between body mass index (BMI) and cancer risk by gender.We are currently taking these observations further by estimating population impact numbers.

Hyperinsulinaemia and alterations of the insulin-like growth factor (IGF) axis are postulated as key altered pathways in the link between obesity and cancer.We have previously quantified the associations between serum total IGF-I and its main binding protein, IGFBP-3 for several cancer types including colorectal, prostate, lung and pre- and post-menopausal breast cancer (Renehan et al. Lancet 2004). We have shown that the IGF axis is significantly influenced in gender-specific ways by factors such as smoking, body mass index and HRT.We have also extensively studied the link between acromegaly, an endocrine disorder characterised by sustained hypersecretion of growth hormone and IGF-I, and colorectal cancer risk. Current studies are focusing on deriving murine models of diet- and genetically-induced obesity and studying tumour promotion and progression in the context of an obese environment.

Preclinical models of biomarker and targeted therapy: Within the Clinical and Experimental Pharmacology group (Prof Caroline Dive) at the Paterson Institute for Cancer Research, Manchester Cancer Research Centre, I lead the Colorectal Cancer (CRC) Focus group.This new group aims: (i) to perform ‘fit for purpose’ evaluation of CEP validated biomarker assays among cohorts of CRC patients from early through to advanced stages of disease; (ii) to evaluate ‘fit for purpose’ biomarkers in response to mechanistic biological therapies (MBTs) in combination regimen clinical trials and ultimately to test the hypothesis that these biomarkers act as surrogates of tumour response; (iii) to develop modelling systems in order to select prospectively MBTs with which to treat a greater proportion of patients in trials effectively according to their tumour biomarker profile, and, conversely, to suspend ineffective agents in biomarker-driven phase II/III trials; and (iv) to expand the development of ‘composite biomarkers’ to enhance all objectives above.

Systematic review and meta-analysis: Systematic review (SR) is the unbiased appraisal of systematically identified relevant studies.Implicit in its definition is a robust and scientifically valid process.We use it as an important research tool. I am co-chair Systematic Review Research and Educational Network (SyREN).

Clinical studies in colorectal cancer and pelvic malignancies:I am lead for clinical research in Colorectal Surgery and the Peritoneal Tumour Service, at the Christie, in collaboration with Miss Sarah T O’Dwyer and other GI/ surgical clinical team members.The workstreams reflect the clinical workload of this tertiary referral practice: management of anal cancer, outcome and quality of life following pelvic exenterative surgery, and after cytoreductive surgery and intra-operative chemotherapy for peritoneal surface malignancies.

We have extensively quantified the potential benefits of intensive follow-up after colorectal cancer, demonstrating that it is associated with improved survival. We are now extending this research theme to address survivorship issues.

 

Methodological Knowledge

  • Basic science methods
  • Systematic review and meta-analysis
  • Biomarker development
  • Clinical trials
  • Clinical studies in surgical oncology
 

Teaching

MB ChB:
Supervisor for Yr 4 Project options
Final year revision course

Clinical postgraduate:
Supervisor & Mentor for junior staff in clinical surgery
Supervisor for MD / PhD students

Non-clinical postgraduate:
Creator of applied biomarker statistical course
Supervisor for MD / PhD students

 

Biography

Dr Andrew Renehan holds dual qualifications in dental surgery and medicine (honours in both). He graduated from Manchester University in 1995, and following his basic surgical training, he undertook his PhD thesis (1998 to 2001) in the laboratories of Professor Chris Potten, Epithelial Biology Group, at the Paterson Institute for Cancer Research, and the Departments of Colorectal Surgery (Miss Sarah T O’Dwyer) and Endocrinology (Professor Steve Shalet), Christie Hospital, Manchester. The title was “Insulin-like growth factors (IGFs) and their binding proteins in colorectal carcinogenesis: with particular reference to cell proliferation and apoptosis”.

After his PhD, he returned to clinical higher surgical training in the North West deanery gaining his CCT in October 2006. He was awarded a HEFCE “new blood” senior lectureship to the University of Manchester which commenced in January 2007. He holds the British Travelling Fellowship (for Coloproctology) for 2009.

 

Collaborators and affiliated staff

University of Manchester

Other universities

  • Professor Matthias Egger, University of Bern, Switzerland
  • Dr Jan Frystyk, University of Aarhus, Denmark
  • Dr Susan Jebb, MRC Nutrition Research Unit, University of Cambridge
  • Dr Georg Luebeck, Fred Hutchinson Cancer Research Center, Seattle, USA
 

Publications

2012

  • Greystoke, A., Dean, E., Saunders, M., Cummings, J., Hughes, a., Ranson, M., Dive, C. & Renehan, A (2012). Qualification of circulating biomarkers of cell death in patients with surgically treated and metastatic colorectal cancer [submitted]. Neolasia, eScholarID:150460
  • Johnson, J., Carstensen, B., Witte, B., Bowker, S., Lipscombe, L. & Renehan, A (2012). Framework paper (1): Evaluating the Temporal Relationship Between Type 2 Diabetes and Cancer Incidence [provisioanlly accepted]. Diabetologia, eScholarID:150445
  • Liong, S., Kocchar, R., Renehan, A. & Manoharan, P (2012). The utility FDG PET/CT in the management of recurrent colorectal cancer [in press]. Australian and New Zealand Journal of Surgery, eScholarID:150461
  • McDonald, , Renehan, A., ST, O. & Haboubi, N (2012). Lymph node harvest in colon and rectal cancer: Current Considerations [in press]. World Journal of Surgical Gastroenterology, eScholarID:150455 | DOI:10.4240/wjgs.v4.i1.9
  • McDonald, J., O'Dwyer, S., Rout, S., Chakrabarty, B., Sikand, K., Fulford, P., Wilson, M. & Renehan, A (2012). Prophylactic cytoreductive surgery for a subtype of low-grade appendiceal mucinous neoplasms [under revision]. British Journal of Surgery, eScholarID:150457
  • Renehan, A (2012). Insulin analogues and cancer risk: the emergence of second-generation studies. Diabetologia, 55(1), 7-9. eScholarID:150453 | DOI:10.1007/s00125-011-2352-9 [doi]
  • Renehan, A., Flood, A., Adams, K., Hollenbeck, A., Schatzkin, A. & Leitzmann, M (2012). Body mass index at dfferent adult ages, weight change and colorectal cancer risk in the NIH-AARP cohort [accepted]. Am J Epid, eScholarID:150443
  • Renehan, A., Solomon, M., Zwahlen, M., Morjaria, R., Whatmore, A., Audí, L., Binder, G., Blum, W., Bougnères, P., Dos Santos, C., Carrascosa, A., Hokken-Koelega, A., Jorge, A., Mullis, P., Tauber, M., Patel, L. & Clayton, P (2012). Growth Hormone (GH) Receptor Polymorphism and GH Therapy Response in Children: a Bayesian meta-analysis [in press]. American Journal of Epidemiology, eScholarID:150448
  • Renehan, A., Yeh, H., Johnson, J., Wild, S., Gale, E. & Møller, H (2012). Framework paper (2): Evaluating the Impact of Diabetes on Mortality in Patients with Cancer [provisionally accepted]. Diabetologia, eScholarID:150444
  • Renehan, A., Zwahlen, M. & Egger, M (2012). Obesity and cancer: epidemiological observations driving mechanistic questions [commissioned]. Nature Reviews Cancer, eScholarID:150454

2011

  • Brush, J., Boyd, K., Chappell, F., Crawford, F., Dozier, M., Fenwick, E., Glanville, J., McIntosh, H., Renehan, A., Weller, D. & Dunlop, M (2011). The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess, 15(35), 1-192. eScholarID:150463 | DOI:10.3310/hta15350 [doi]
  • Burgers, A., Biermasz, N., Schoones, J., Pereira, A., Renehan, A., Zwahlen, M., Egger, M. & Dekkers, O (2011). Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (igf-I) and mortality. J Clin Endocrinol Metab, 96(9), 2912-20. eScholarID:150456 | DOI:jc.2011-1377 [pii] 10.1210/jc.2011-1377 [doi]
  • Clayton, P., Banerjee, I., Murray, P. & Renehan, A (2011). Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol, 7(1), 11-24. eScholarID:150449 | DOI:10.1038/nrendo.2010.171
  • Crosbie, E., Roberts, C., Qian, W., Swart, A., Kitchener, H. & Renehan, A (2011). Body mass index does not influence post-treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial. Eur J Cancer, eScholarID:150446 | DOI:10.1016/j.ejca.2011.10.003
  • Grossmann, , Verberne, , de Bock, , Havenga, , Kema, , Klaase, , Renehan, & Wiggers, T (2011). The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper. Cancers, eScholarID:150462 | DOI:10.3390/cancers3022302
  • Lancashire, L., Roberts, D., Dive, C. & Renehan, A (2011). The development of composite circulating biomarker models for use in anticancer drug clinical development. Int J Cancer, 128(8), 1843-51. eScholarID:150459 | DOI:10.1002/ijc.25513 [doi]
  • Renehan, A (2011). Cumulative incidence of metachronous colorectal cancer risk for mismatch repair gene mutation carriers is overestimated. Gut, eScholarID:150447 | DOI:gutjnl-2011-300997 [pii] 10.1136/gutjnl-2011-300997 [doi]
  • Renehan, A (2011). Height and cancer: consistent links, but mechanisms unclear. Lancet Oncol, 12(8), 716-7. eScholarID:150450 | DOI:S1470-2045(11)70193-0 [pii] 10.1016/S1470-2045(11)70193-0 [doi]
  • Renehan, A. & Dive, C (2011). Obesity, insulin and chemoresistance in colon cancer. DOI: 10.3978/j.issn.2078-6891.2011.010. Journal of Gastrointestinal Oncology, 2, 8-10. eScholarID:150458
  • Renehan, A. & O'Dwyer, S (2011). Initial management through the anal cancer multidisciplinery team meeting. Colorectal Disease, 13(s1), 21-28. eScholarID:150452 | DOI:DOI: 10.1111/j.1463-1318.2010.02495.x
  • Renehan, A. & O'Dwyer, S (2011). Management of local disease relapse. Colorectal Disease, 13(s1), 44-52. eScholarID:150451 | DOI:DOI: 10.1111/j.1463-1318.2010.02500.x

2010

  • Renehan, A (2010). Obesity and cancer. In Leff, T. & Granneman, J. (Ed.), Adipose Tissue in Health and Disease. New York: Wiley-VCH. eScholarID:116035
  • Renehan, A (2010). The epidemiology of overweight/obesity and cancer risk. In McTiernan, A. (Ed.), Physical Activity, Dietary Calorie Restriction, and Cancer. New York: Springer. eScholarID:116032
  • Coebergh, J., Martin-Moreno, J., Soerjomataram, I. & Renehan, A (2010). The long road towards cancer prevention: 4 steps backward and 8 forward. Eur J Cancer, 46(14), 2660-2. eScholarID:116033 | DOI:S0959-8049(10)00732-X [pii] 10.1016/j.ejca.2010.07.037 [doi]
  • Crosbie, E., Zwahlen, M., Kitchener, H., Egger, M. & Renehan, A (2010). Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 19(12), 3119-30. eScholarID:116021 | DOI:1055-9965.EPI-10-0832 [pii] 10.1158/1055-9965.EPI-10-0832 [doi]
  • de Vries, E., Soerjomataram, I., Lemmens, V., Coebergh, J., Barendregt, J., Oenema, A., Moller, H., Brenner, H. & Renehan, A (2010). Lifestyle changes and reduction of colon cancer incidence in Europe: A scenario study of physical activity promotion and weight reduction. Eur J Cancer, 46(14), 2605-16. eScholarID:116030 | DOI:S0959-8049(10)00735-5 [pii] 10.1016/j.ejca.2010.07.040 [doi]
  • Harvie, M., Renehan, A., Frystyk, J., Flyvbjerg, A., Mercer, T., Malik, R., Adams, J., Cuzick, J. & Howell, A (2010). Increase in serum total IGF-I and maintenance of free IGF-I following intentional weight loss in pre-menopausal women at increased risk of breast cancer. BMC Open Journal of Obesity, eScholarID:116028 | DOI:10.2174/1876823701002020063
  • Lancashire, L., Roberts, D., Dive, C. & Renehan, A (2010). The development of composite circulating biomarker models for use in anti-cancer drug clinical development. Int J Cancer, eScholarID:116031 | DOI:10.1002/ijc.25513 [doi]
  • Meza, R., Jeon, J., Renehan, A. & Luebeck, E (2010). Colorectal Cancer Incidence Trends in the United States and United Kingdom: Evidence of Right- to Left-Sided Biological Gradients with Implications for Screening. Cancer Res, 70(13), 5419-5429. eScholarID:116025 | DOI:0008-5472.CAN-09-4417 [pii] 10.1158/0008-5472.CAN-09-4417 [doi]
  • Renehan, A (2010). Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer (Br J Surg 2010; 97: 1407-1415). Br J Surg, 97(9), eScholarID:116020 | DOI:10.1002/bjs.7129 [doi]
  • Renehan, A (2010). Body fatness and bevacizumab-based therapy in metastatic colorectal cancer. Gut, 59(3), 289-90. eScholarID:116022 | DOI:59/3/289 [pii] 10.1136/gut.2009.197210 [doi]
  • Renehan, A (2010). Obesity and cancer in Asia-Pacific populations. Lancet Oncol, 11(8), 704-5. eScholarID:116037 | DOI:S1470-2045(10)70148-0 [pii] 10.1016/S1470-2045(10)70148-0 [doi]
  • Renehan, A., Egger, M. & Zwahlen, M (2010). Body mass index and cancer risk: the evidence for causal association. BMC Open Journal of Obesity, eScholarID:116024 | DOI:10.2174/1876823701002020012
  • Renehan, A., Smith, U. & Kirkman, M (2010). Linking diabetes and cancer: a consensus on its complexity [commentary]. Lancet, 375(9733), 2201-02. eScholarID:116036 | DOI:10.1016/S0140-6736(10)60706-4
  • Renehan, A., Soerjomataram, I. & Leitzmann, M (2010). Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. Eur J Cancer, 46(14), 2581-92. eScholarID:116029 | DOI:S0959-8049(10)00780-X [pii] 10.1016/j.ejca.2010.07.052 [doi]
  • Renehan, A., Soerjomataram, I., Martin-Moreno, J. & Coebergh, J (2010). Foreword: Implementing cancer prevention in Europe. Eur J Cancer, 46(14), 2523-4. eScholarID:116026 | DOI:S0959-8049(10)00737-9 [pii] 10.1016/j.ejca.2010.07.042 [doi]
  • Renehan, A., Soerjomataram, I., Tyson, M., Egger, M., Zwahlen, M., Coebergh, J. & Buchan, I (2010). Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer, 126(3), 692-702. eScholarID:116027 | DOI:10.1002/ijc.24803 [doi]
  • Roberts, D., Dive, C. & Renehan, A (2010). Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med, 61, 301-16. eScholarID:116023 | DOI:10.1146/annurev.med.080708.082713 [doi]

2009

  • Harriss DJ, Atkinson G, Batterham A, George K, Tim Cable N, Reilly T, Haboubi N, Renehan A. (2009). Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. Colorectal Dis, eScholarID:1d18473 | DOI:10.1111/j.1463-1318.2009.01767.x
  • Harriss, D, Atkinson, G, George, K, Tim Cable, N, Reilly, T, Haboubi, N, Zwahlen, M, Egger, M, Renehan, A, NULL. (2009). Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. Colorectal Dis, eScholarID:1d18472 | DOI:10.1111/j.1463-1318.2009.01766.x
  • Renehan A. (2009). Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncol, 10( 7), eScholarID:1d19951 | DOI:10.1016/S1470-2045(09)70170-6
  • Rout, S., Renehan, A., Parkinson, M., Saunders, M., Fulford, P., Wilson, M. & O'Dwyer, S (2009). Treatments and outcomes of peritoneal surface tumors through a centralized national service (United kingdom). Dis Colon Rectum, 52(10), 1705-14. eScholarID:116034 | DOI:10.1007/DCR.0b013e3181b5504e [doi] 00003453-200910000-00004 [pii]

2008

  • Farquharson, A, Pranesh, N, Witham, G, Swindell, R, Taylor, M, Renehan, A, Rout, S, Wilson, M, O'Dwyer, S, Saunders, M. (2008). A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer, 99( 4), 591-6. eScholarID:1d32623 | DOI:10.1038/sj.bjc.6604522
  • Greystoke A, Cummings J, Ward T, Renehan A. (2008). Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol, 19, 990-5. eScholarID:1d18477 | DOI:10.1093/annonc/mdn014
  • Renehan A, Berster J. (2008). Insulin and Cancer: Report of the Proceedings of the First International Workshop, October 27-28, 2007, Düsseldorf, Germany. Pediatr Endocrinol Rev, 5( 3), eScholarID:1d19953
  • Renehan A, Roberts DL, Dive C. (2008). Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem, 114( 1), eScholarID:1d19952 | DOI:10.1080/13813450801954303
  • Renehan A, Tyson M, Egger M, Heller R, Zwahlen M. (2008). Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet, 371( 9612), 569-78. eScholarID:1d18474 | DOI:10.1016/S0140-6736(08)60269-X
  • Rout S, Renehan A, Parkinson M. (2008). The treatments and outcomes of peritoneal tumours through a centralised national service. Dis Colon Rectum, eScholarID:1d33108
  • Seenath M, Roberts DL, Cawthorne C, Saunders M, Armstrong G, O'Dwyer S, Stratford IJ, Dive C, Renehan A. (2008). Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein Bid in ex vivo colorectal cancer. Br J Cancer, 99( 3), 459-63. eScholarID:1d17622
  • Renehan A, Brennan B. (2008). Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab, 22( 4), eScholarID:17d367 | DOI:10.1016/j.beem.2008.08.011

2007

  • Renehan A, Frystyk J, Howell A, O'dwyer S, Shalet S, Flyvbjerg A. (2007). The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. Growth Horm IGF Res, 17( 3), 210-9. eScholarID:1d18476 | DOI:10.1016/j.ghir.2007.01.017
  • Renehan A, Luebeck G. (2007). Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches. Colorectal Dis, 9( 5), 393-6. eScholarID:1d18475 | DOI:10.1111/j.1463-1318.2007.01214.x

2006

  • Bibi R, Pranesh N, Saunders M, Wilson M, O'dwyer S, Stern PL, Renehan A. (2006). A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer, 95( 9), 1258-64. eScholarID:1d30911
  • O'dwyer S, Renehan A, Zwahlen M, Egger M. (2006). Risk of second primary colorectal cancer with particular reference to age at diagnosis. Colorectal Dis, 8( 9), eScholarID:1d30918
  • Renehan A, Frystyk J, Flyvbjerg A. (2006). Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab, 17( 8), 328-36. eScholarID:1d31594
  • Renehan A, Harvie M, Howell A-. (2006). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer, 13( 2), 273-8. eScholarID:1d31034
  • Renehan A, Wille-Jørgensen P. (2006). Towards a more prescriptive follow-up regimen for colorectal cancer. Colorectal Dis, 8(8), 623-625. eScholarID:1d31017

2005

  • Renehan A, Egger M, Minder C, O'Dwyer S, Shalet S, Zwahlen M. (2005). IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. Int J Cancer, 115( 6), 1006-7; author reply 1008. eScholarID:1d31499
  • Renehan A, Egger M, Saunders M, O'Dwyer S. (2005). Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer, 92( 3), 430-3. eScholarID:1d30382
  • Renehan A, Howell A-. (2005). Preventing cancer, cardiovascular disease, and diabetes. Lancet, 365( 9469), 1449-51. eScholarID:1d29540
  • Renehan A, Painter J, Bell G, Rowland R, O'Dwyer S, Shalet S. (2005). Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clin Endocrinol (Oxf), 62( 3), 323-30. eScholarID:1d30381
  • Renehan A, Saunders M, Schofield P, O'Dwyer S. (2005). Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg, 92( 5), 605-14. eScholarID:1d30374
  • Renehan A, Shalet S. (2005). Diabetes, insulin therapy, and colorectal cancer. BMJ, 330( 7491), 551-2. eScholarID:1d30380
  • Renehan A. (2005). Insulin-like growth factor-binding protein-3, breast cancer risk, and different serum assays. Cancer Epidemiol Biomarkers Prev, 14( 7), eScholarID:1d30279
  • Wille-Jørgensen P, Renehan A. (2005). Systematic reviews: challenging dogmas and uncovering potential harms. Colorectal Dis, 7( 1), 1-3. eScholarID:1d29976

2004

  • Renehan A, Atkin W, O'dwyer S, Shalet S. (2004). The effect of cigarette smoking use and cessation on serum insulin-like growth factors. Br J Cancer, 91( 8), 1525-31. eScholarID:1d30134
  • Renehan A, O'Dwyer S, Whynes D. (2004). Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ, 328( 7431), eScholarID:1d30383
  • Renehan A, Wille-Jørgensen P. (2004). Systematic review, Cochrane and Colorectal Disease. Colorectal Dis, 6( 2), 73-4. eScholarID:1d29977
  • Renehan A, Zwahlen M, Minder C, O'Dwyer S, Shalet S, Egger M. (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363( 9418), 1346-53. eScholarID:1d30135

2003

  • Duff S, Li C, Renehan A, O'Dwyer S, Kumar S. (2003). Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int J Oncol, 22( 2), 339-43. eScholarID:1d30281
  • Li C, Gardy R, Seon B, Duff S, Abdalla S, Renehan A, O'Dwyer S, Haboubi N, Kumar S. (2003). Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer, 88( 9), 1424-31. eScholarID:1d12123 | DOI:10.1038/sj.bjc.6600874
  • McGurk M, Thomas B, Renehan A. (2003). Extracapsular dissection for clinically benign parotid lumps: reduced morbidity without oncological compromise. Br J Cancer, 89( 9), 1610-3. eScholarID:1d30375
  • Renehan A, Jones J, O'Dwyer S, Shalet S. (2003). Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. Growth Horm IGF Res, 13( 6), 341-6. eScholarID:1d30390
  • Renehan A, O'Connell J, O'Halloran D, Shanahan F, Potten C, O'Dwyer S, Shalet S. (2003). Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res, 35( 11-12), 712-25. eScholarID:1d31500
  • Renehan A, O'Dwyer S, Shalet S. (2003). Guidelines for colonoscopic screening in acromegaly are inconsistent with those for other high risk groups. Gut, 52( 7), 1071-2; author reply 1072. eScholarID:1d30280

2002

  • Parkinson C, Renehan A, Ryder W, O'Dwyer S, Shalet S, Trainer P. (2002). Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf), 57( 1), 59-64. eScholarID:1d31018
  • Renehan A, Egger M, Saunders M, O'Dwyer S. (2002). Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ, 324( 7341), eScholarID:1d31066
  • Renehan A, O'Dwyer ST, Haboubi NJ, Potten CS. (2002). Early cellular events in colorectal carcinogenesis. Colorectal Dis, 4( 2), 76-89. eScholarID:1d30336
  • Renehan A, Shalet S. (2002). Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab, 87( 4), eScholarID:1d31083
  • Renehan A. (2002). Gender differences in long-term survival of patients with colorectal cancer. Br J Surg, 89( 4), 489-90. eScholarID:1d31019

2001

  • Renehan A, Bach S, Potten C. (2001). The relevance of apoptosis for cellular homeostasis and tumorigenesis in the intestine. Can J Gastroenterol, 15( 3), 166-76. eScholarID:1d31146
  • Renehan A, Booth C, Potten C. (2001). What is apoptosis, and why is it important? BMJ, 322( 7301), 1536-8. eScholarID:1d31125
  • Renehan A, Odwyer S, Shalet S. (2001). Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf), 55( 6), 731-3. eScholarID:1d31124
  • Renehan A, Painter J, Atkin W, Potten C, Shalet S, O'Dwyer S. (2001). High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg, 88( 1), 107-13. eScholarID:1d31067
  • Renehan A, Toogood A, Ryder W, Jones J, Potten C, O'Dwyer S, Shalet S. (2001). Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clin Endocrinol (Oxf), 55( 4), 469-75. eScholarID:1d31084

Top of page

| Skip to main content | Skip to navigation | Skip to Search |